SUPPLEMENTARY DATA from A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
Year: 2023
Type: supplementary-materials
Abstract: SUPPLEMENTAL APPENDIX Supplemental Table 1. Phase I Abexinostat Dosing Schedule and Dose Levels. Supplemental Table 2. Dose-Limiting Toxicities. Supplemental Table 3. Adverse Events of {greater than or equal to} Grade 3 (Phase I All-treated Population). Supplemental Table 4. Adverse Events of {greater than or equal to} Grade 3 (Phase II All-treated Population)
Authors: Andrew M. Evens, Sriram Balasubramanian, Julie M. Vose, Wael Harb, Leo I. Gordon, Robert Langdon, Julian Sprague, Mint Sirisawad, Chitra Mani, Jeanne Yue, Ying Luan, Sharon Horton, Thorsten Graef, Nancy L. Bartlett
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361884446